Testing Several Alzheimer's Drugs at Once: Why New "Platform" Trials Matter
Friday, October 23, 2026
For decades, Alzheimer's research has mostly worked like this: one drug, one trial, one answer, often a decade later. This week brought news of a faster approach on both sides of the Atlantic.
What happened. On October 22, the UK launched AD-SMART, a national trial led by the UK Dementia Research Institute at Imperial College London and Alzheimer's Research UK. Instead of testing a single medicine, it tests several at the same time, with every group compared against one shared placebo group. Results are checked regularly, and any drug that isn't showing clear benefit can be dropped and replaced with a new candidate. It starts with two medicines already approved for other conditions, one for type 2 diabetes and one for ADHD, so if either helps, it could reach patients faster than a brand-new drug. The same design has already been used in motor neurone disease (ALS). (Source: Imperial College London, October 22, 2026.)
The same day in the U.S., the Advanced Research Projects Agency for Health (ARPA-H) announced up to $48.8 million for new Alzheimer's projects. They include a biomarker-guided trial platform at Mass General Brigham to test several prevention treatments at once in people who don't yet have symptoms, and an open-data research platform at Washington University in St. Louis. (Source: ARPA-H, October 22, 2026.)
Why it matters. Faster trials mean faster answers, including the honest answer "this doesn't work," which frees time and volunteers for the next idea. For volunteers, sharing one placebo group across several drugs can mean a better chance of getting an active treatment.
What it does not mean. No new treatment has been proven here. These are trials that are just starting, and results are likely years away. Please don't ask a doctor to prescribe diabetes or ADHD medicines "for Alzheimer's" based on this news; whether they help is exactly what the trial is meant to find out. We've added a short section on these new designs to our guide to joining a clinical trial.
Try this today: spend 10 minutes on a trial match
You don't need a diagnosis to help research; many studies need healthy volunteers and caregivers too. The Alzheimer's Association's free TrialMatch service asks a few questions and suggests studies near you (or call 800-272-3900). Write down any study that looks interesting and bring it to your next doctor visit to talk it over. Signing up to hear about studies doesn't commit you to joining one.
Thanks for reading, and have a good weekend. We'll see you tomorrow.
Ask a question
Have a question about memory, Alzheimer's, or caregiving? Email us at:
Open in my email app · Write in Gmail (opens in a new tab)
We may answer common questions in future updates (we won't share your name). We can't give personal medical advice; for urgent help call the Alzheimer's Association Helpline at 800-272-3900.